<DOC>
	<DOCNO>NCT00243594</DOCNO>
	<brief_summary>Dendritic cell ( DCs ) professional antigen-presenting cell immune system . As currently use clinical vaccination protocol cancer patient , immunological clinical response observe . For therapy accurate delivery target organs essential . Correct delivery subsequent migration vaccinate DCs regional lymph node paramount importance effective stimulation immune system . Currently know best route administration DC vaccine . Using magnetically label DCs , investigate potential MRI cell track monitor DC therapy . This investigated stage III/IV melanoma patient regional lymph node dissection schedule . Autologous monocyte-derived DCs label clinically approve superparamagnetic iron oxide ( SPIO ) formulation Endorem 111In-oxine inject either skin directly lymph node ultrasound guidance . Two day vaccination patient monitor scintigraphy MR imaging . Lymph nodes resect . Subsequently patient receive 3 vaccination DCs . During therapy immune response use melanoma peptide monitor .</brief_summary>
	<brief_title>Dendritic Cell Vaccination Melanoma Patients Scheduled Regional Lymph Node Dissection</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Inclusion criterion : Histologically document evidence melanoma Stage IIIIV melanoma accord 2001 AJCC criterion Radical lymph node dissection plan , either curative ( stage III ) palliative ( stage IV ) intent Melanoma express gp100 ( compulsory ) tyrosinase ( noncompulsory ) HLAA2.1 phenotype accord lymphocyte HLA type ECOG performance status 01 , life expectancy &gt; 3 month Age 1875 year Interval since last prior chemotherapy , immunotherapy radiotherapy least 4 week , residual toxicity prior treatment . WBC &gt; 3.0 x 109/l , lymphocytes &gt; 0.8 x 109/l , platelet &gt; 100 x 109/l , serum creatinine &lt; 150 μmol/l , serum bilirubin &lt; 25 μmol/l Written inform consent Expected adequacy followup Exclusion criterion : No clinical sign CNS metastasis , patient clinical suspicion metastases diagnostic test perform exclude . No concomitant use corticosteroid immunosuppressive agent No history second malignancy within last 5 year . Adequately treat basal carcinoma skin carcinoma situ cervix acceptable within period No serious concomitant disease , active infection . No autoimmune disease organ allograft , clinical suspicion HIV Hepatitis B No contraindication MRIscanning : claustrophobia , pacemaker pacemaker thread , cerebral clip artificial heartvalves , internal hearing prosthesis No known allergy shell fish ( contains KLH ) No pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Dendritic cell</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Peptides</keyword>
	<keyword>MRI</keyword>
	<keyword>Scintigraphy</keyword>
	<keyword>Immune response</keyword>
</DOC>